Open AccessRituximab Therapy for Membranous Nephropathy
Author(s) -
Andrew S. Bomback,
Vimal K. Derebail,
Julie Anne G. McGregor,
Abhijit V. Kshirsagar,
Ronald J. Falk,
Patrick H. Nachman
Publication year - 2009
Publication title -
clinical journal of the american society of nephrology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.05231008
Subject(s) - rituximab , medicine , membranous nephropathy , adverse effect , proteinuria , immunosuppression , renal function , concomitant , calcineurin , urology , oncology , transplantation , kidney , lymphoma
The treatment of membranous nephropathy (MN) remains controversial. Rituximab, which selectively targets B cells, has emerged as a possible alternative treatment option with limited toxicity.